PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+9.02%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.15B
AUM Growth
+$1.15B
(-11%)
Cap. Flow
-$191M
Cap. Flow
% of AUM
-16.56%
Top 10 Holdings %
Top 10 Hldgs %
54.46%
Holding
82
New
17
Increased
13
Reduced
24
Closed
24
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$20.8M |
| 2 |
Natera
NTRA
|
$17.1M |
| 3 |
Cencora
COR
|
$16M |
| 4 |
Masimo
MASI
|
$15.9M |
| 5 |
Akero Therapeutics
AKRO
|
$14.2M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$61.6M |
| 2 |
AbbVie
ABBV
|
$54M |
| 3 |
Elevance Health
ELV
|
$38.4M |
| 4 |
argenx
ARGX
|
$34M |
| 5 |
Universal Health Services
UHS
|
$29.2M |
Sector Composition
| 1 | Healthcare | 96.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$657B
| $209M | 17.79% | 268,023 -5,755 | -2% | -$4.49M |
|
2
Tenet Healthcare
THC
$16.3B
| $87.9M | 7.48% | 499,243 +7,909 | +2% | +$1.39M |
|
3
McKesson
MCK
$85.4B
| $53M | 4.51% | 72,313 -25,185 | -26% | -$18.5M |
|
4
Axsome Therapeutics
AXSM
$6.05B
| $50.4M | 4.29% | 483,105 -73,440 | -13% | -$7.67M |
|
5
Intuitive Surgical
ISRG
$170B
| $48.3M | 4.12% | 88,967 -4,106 | -4% | -$2.23M |
|
6
Penumbra
PEN
$10.6B
| $42.7M | 3.63% | 166,261 | – | – |
|
7
Ascendis Pharma
ASND
$11.8B
| $38.3M | 3.26% | 221,754 +34,838 | +19% | +$6.01M |
|
8
Soleno Therapeutics
SLNO
$3.6B
| $34.1M | 2.9% | 407,202 -188,004 | -32% | -$15.8M |
|
9
CVS Health
CVS
$92.8B
| $33M | 2.81% | 479,005 +166,700 | +53% | +$11.5M |
|
10
Outset Medical
OM
$247M
| $32M | 2.72% | 1,664,727 -21,000 | -1% | -$403K |
|
11
Danaher
DHR
$147B
| $31.9M | 2.71% | 161,413 +48,938 | +44% | +$9.67M |
|
12
Edwards Lifesciences
EW
$47.8B
| $30.7M | 2.61% | 392,503 +12,549 | +3% | +$981K |
|
13
HCA Healthcare
HCA
$94.5B
| $27.7M | 2.36% | 72,290 -5,174 | -7% | -$1.98M |
|
14
Humana
HUM
$36.5B
| $26.8M | 2.28% | 109,511 +46,273 | +73% | +$11.3M |
|
15
Molina Healthcare
MOH
$9.8B
| $25.5M | 2.17% | 85,739 +15,651 | +22% | +$4.66M |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $23.6M | 2% | 72,220 -14,925 | -17% | -$4.87M |
|
17
BridgeBio Pharma
BBIO
$9.89B
| $22.5M | 1.92% | 521,793 -386,342 | -43% | -$16.7M |
|
|
18
Teva Pharmaceuticals
TEVA
$21.1B
| $20.8M | 1.77% | +1,238,846 | New | +$20.8M |
|
19
Indivior
INDV
$3.03B
| $20M | 1.7% | 1,355,931 +196,098 | +17% | +$2.89M |
|
|
20
Natera
NTRA
$23.1B
| $17.1M | 1.46% | +101,250 | New | +$17.1M |
|
|
21
Cencora
COR
$56.5B
| $16M | 1.36% | +53,287 | New | +$16M |
|
|
22
Masimo
MASI
$7.59B
| $15.9M | 1.35% | +94,451 | New | +$15.9M |
|
23
Oscar Health
OSCR
$4.31B
| $15.8M | 1.34% | 735,033 -125,788 | -15% | -$2.7M |
|
24
Waters Corp
WAT
$18B
| $15M | 1.28% | 43,089 -8,769 | -17% | -$3.06M |
|
|
25
Akero Therapeutics
AKRO
$3.74B
| $14.2M | 1.21% | +266,167 | New | +$14.2M |
|